Gastro-esophageal Reflux Disease Clinical Trial
Official title:
Translation and Validation of the PASS Test for Gastro-esophageal Reflux Disease (GERD) Patients With Partial Response to PPI in Chinese Population: PASS-HK
The PASS test is only available and valid tool for the evaluation of persistent acid-related
symptoms in patients receiving PPI therapy. There is lack of a validated Chines version of
PASS questionnaire for the GERD patients with partial response to proton pump inhibitor
(PPI). The English version of PASS test will be translated to traditional Chinese by using
forward-backward procedure, and the Chinese version of PASS test will be validated its
psychometric properties in Hong Kong population.
Eligible subjects will be invited to administer questionnaires to evaluate the psychometric
properties of the Chinese version of PASS test.
Gastro-esophageal reflux disease (GERD) is a common condition defined as symptoms or mucosal
damage produced by the abnormal reflux of gastric contents into the esophagus. Symptoms
highly specific for GERD are heartburn, regurgitation, or both, which often occur after
meals. The prevalence of GERD is around 20% for weekly reflux symptoms in the Western
population, while 9.3% in Chinese population. However, approximately 20-30% of patients with
GERD experience only a partial response of their heartburn of regurgitation symptoms to PPI
therapy.
There is lack of a validated Chines version of PASS questionnaire for the GERD patients with
partial response to PPI.
Before a treatment response assessment tool can be used clinically, various questions on
reliability and validity of the instrument need to be addressed. The aims of this study are
(1) to translate the PASS test from English to traditional Chinese, named PASS-HK, and (2) to
assess the psychometric properties of the PASS-HK, before clinical application.
Linguistic translation of the PASS questionnaire from English to Chinese version will follow
a forward-backward procedure.
After finalization of Chinese version of the PASS (PASS-HK), the reliability of PASS-HK will
be evaluated for internal consistency using Cronbach's alpha. The intraclass correlation
coefficient was calculated within 14 days for two surveys in order to evaluate the
reproducibility of the results under constant conditions. Pearson product moment correlation
coefficient will be used to evaluate whether PASS-HK can measure what it claims to measure by
comparing with SF-12v2, GERD QOL and GREDSQ scores.
All eligible subjects will be invited to complete PASS-HK twice within 14 days under a stable
condition. In addition to PASS-HK, all patients will have to complete SF-12v2, GERD-QOL,
GERDQ and GERDSQ questionnaires.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03596476 -
Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy
|
N/A | |
Completed |
NCT02456779 -
Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD
|
N/A | |
Completed |
NCT02114216 -
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03788109 -
Relationship Between Gastric Accommodation, TLESRs and Reflux in HV and in GERD With or Without Overlapping Dyspepsia
|
N/A | |
Completed |
NCT01560910 -
Detection of Minimal Change Esophagitis by I-scan
|
N/A | |
Recruiting |
NCT03824548 -
Outcomes for Patients With Gastro-Esophageal Reflux Disease
|
||
Completed |
NCT01867931 -
Epithelial Damage in GERD
|
N/A |